•IV: zoledronic acid (yearly) — for noncompliant or GERD
•Mechanism: bind to bone hydroxyapatite → inhibit osteoclast
•Take with full glass of water, sit upright × 30 min, empty stomach — prevents esophagitis
•Side effects: esophagitis (oral), flu-like with first IV dose, atypical FEMUR fracture (long use), OSTEONECROSIS of the JAW (esp dental work), hypocalcemia
•Drug holiday after 5 years (oral) or 3 years (IV) in low-risk patients
◆Denosumab (RANK-L inhibitor)
•SC every 6 months
•Mechanism: monoclonal antibody to RANK-L → ↓ osteoclast formation
•Side effects: hypocalcemia (replete first), ONJ, atypical fractures, ↑ infections, REBOUND FRACTURES if discontinued (must transition to bisphosphonate)
•Used in CKD where bisphosphonates contraindicated
◆Anabolic agents (build bone)
•Teriparatide (PTH 1–34): SC daily × max 2 years — recombinant PTH; sequential before/after antiresorptive
•Abaloparatide: similar to teriparatide; PTHrP analog